A drug against the Covid it may be ready by the end of June. It is an experimental medicine, called LY-CoV555, which was administered in recent days to a group of patients hospitalized as part of the first study ever carried out on a potential antibody treatment against the SARS-CoV-2 virus.
The news comes straight from overseas and involves two of the largest hospitals and research centers in the United States: the NYU Grossman School of Medicine and the Cedars-Sinai in Los Angeles. The drug, entered in the register ClinicalTrials.gov, the largest clinical trial database managed by the United States National Library of Medicine (NLM), was developed by researchers from the pharmaceutical company Lilly . L’antibody instead, it was identified by the Vaccine Research Center of the National Institute of Allergies and Infectious Diseases (Niaid), the one directed by Anthony Fauci, in collaboration with AbCellera, on a blood sample taken from one of the first American patients recovered from Covid-19.
What does the drug consist of
LY-CoV555 is a drug that involves the use of monoclonal antibodies, that is, proteins of the same and identical matrix produced by plasma or in the tissues of the immune system. Its function is to inhibit access to the virus in the human body in an action to contrast the now famous Sars-COV-2 Spike protein. Potentially, the antibody can be used in both the prevention and treatment of Covid-19. However, its real effectiveness against coronavirus will be tested in the coming months, when the results of the trial are evident. Currently, the drug has been administered intravenously to 32 positive patients who are constantly monitored by researchers at the NYU Grossman School of Medicine and Cedars-Sinai in Los Angeles.
The study results will be available by the end of June. “We are committed to working with our industry partners to generate scientific evidence to meet the urgent need for treatments that reduce the severity of COVID-19 disease. Antibody treatments such as the one studied here promise to be effective medical countermeasures against this deadly infection“Mark Mulligan said on the pages of Sciencefocus.com. Daniel Skovronsky, Lilly’s scientific director and president of Lilly Research Laboratories, continued: “Antibody therapies such as LY-CoV555 may have potential for both the prevention and treatment of COVID-19 and may be particularly important for groups most affected by the disease such as the elderly and those with compromised immune systems.“If the results of Phase 1 show that the antibody can be safely administered, the researchers will study the effects of LY-CoV555 in non-hospitalized COVID-19 patients.